inflammatory bowel disease Archives -

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Phil Taylor Bristol-Myers Squibb, deucravacitinib, GentiBio, Immunology and inflammation, inflammatory bowel disease, partnering, Treg, Zeposia 0 Comment

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for

BMS adds to IBD pipeline with $1.9bn GentiBio deal

https://pharmaphorum.com/news/bms-adds-to-ibd-pipeline-with-1-9bn-gentibio-deal/

News/ News/ Sales and Marketing

AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval

Phil Taylor AbbVie, Crohn's disease, inflammatory bowel disease, regulatory approval, Skyrizi 0 Comment

AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into

AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval

https://pharmaphorum.com/news/abbvies-skyrizi-beats-il-23-rivals-to-crohns-disease-approval/

Open communication helps ulcerative colitis patients through COVID-19

News/ News/ R&D

Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials

Phil Taylor Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, inflammatory bowel disease, Pfizer, ulcerative colitis, Zeposia 0 Comment

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals’ etrasimod

Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials

https://pharmaphorum.com/news/pfizers-arena-buyout-looks-canny-as-etrasimod-aces-phase-3-trials/

News/ News/ R&D

Second trial opens door for Lilly’s mirikizumab in ulcerative colitis

Phil Taylor Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis 0 Comment

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody

Second trial opens door for Lilly’s mirikizumab in ulcerative colitis

https://pharmaphorum.com/news/second-trial-opens-door-for-lillys-mirikizumab-in-ulcerative-colitis/

News/ News/ R&D

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

Phil Taylor AbbVie, Crohn's disease, inflammatory bowel disease, Rinvoq 0 Comment

AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

https://pharmaphorum.com/news/third-positive-trial-sets-up-filings-for-abbvies-rinvoq-in-crohns/

News/ News/ R&D

Lilly unveils mirikizumab data in ulcerative colitis as it preps filings

Phil Taylor Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis 0 Comment

Eli Lilly has reported phase 3 results with its ulcerative colitis challenger mirikizumab, as it waits for the

Lilly unveils mirikizumab data in ulcerative colitis as it preps filings

https://pharmaphorum.com/news/lilly-unveils-mirikizumab-data-in-ulcerative-colitis-as-it-preps-filings/

News/ News/ R&D

Failed IBD trial dents confidence in BMS’ deucravacitinib

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis 0 Comment

Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD)

Failed IBD trial dents confidence in BMS’ deucravacitinib

https://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/

Digital/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Holistic immunology: Supporting patients at every stage of their journey

mike.hammerton@pharmaphorum.com IMID, inflammatory bowel disease, inflammatory diseases, Janssen, Janssen leaders, psoriasis, Rheumatoid arthritis 0 Comment

As part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches to

Holistic immunology: Supporting patients at every stage of their journey

https://pharmaphorum.com/r-d/views-analysis-r-d/holistic-immunology-supporting-patients-at-every-stage-of-their-journey/

A healthy discussion on funding tomorrow’s treatments

News/ News/ Sales and Marketing

Despite biosims, ulcerative colitis drugs still cost too much; ICER

Phil Taylor AbbVie, gastroenterology, Humira, inflammatory bowel disease, Johnson & Johnson, Merck & Co, Pfizer, Takeda, ulcerative colitis 0 Comment

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough

Despite biosims, ulcerative colitis drugs still cost too much; ICER

https://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/

Trending

inflammatory bowel disease

Login